{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:16:36Z","timestamp":1792030596836,"version":"4.4.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Ministry of Science and Technology, Executive Yuan, Taiwan","award":["MOST-109-2314-B-195-024, MOST-108-2314-B-195-012, MOST-108-2314-B-195-014, MOST-106-2314-B-195-015-MY2, and MOST-105-2628-B-195-001-MY3"],"award-info":[{"award-number":["MOST-109-2314-B-195-024, MOST-108-2314-B-195-012, MOST-108-2314-B-195-014, MOST-106-2314-B-195-015-MY2, and MOST-105-2628-B-195-001-MY3"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cardiac abnormalities have been observed in patients with mucopolysaccharidosis type II (MPS II). The aim of this study was to investigate the cardiac features and natural progression of Taiwanese patients with MPS II, and evaluate the impact of enzyme replacement therapy (ERT) on cardiac structure and function.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The medical records and echocardiograms of 48 Taiwanese patients with MPS II (median age, 6.9\u00a0years; age range, 0.1\u201327.9\u00a0years) were reviewed. The relationships between age and each echocardiographic parameter were analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The mean <jats:italic>z<\/jats:italic>-scores of left ventricular mass index (LVMI), interventricular septum diameter in diastole (IVSd), left ventricular posterior wall diameter in diastole (LVPWd), and aortic diameter were 1.10, 2.70, 0.95 and 1.91, respectively. <jats:italic>Z<\/jats:italic> scores\u2009&gt;\u20092 were identified in 33%, 54%, 13%, and 46% for LVMI, IVSd, LVPWd, and aortic diameter, respectively. The most prevalent cardiac valve abnormality was mitral regurgitation (MR) (56%), followed by aortic regurgitation (AR) (33%). The severity of mitral stenosis (MS), MR, aortic stenosis (AS), AR, and the existence of valvular heart disease were all positively correlated with increasing age (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). We also compared the echocardiographic parameters between two groups: (1) 12 patients who had up to 17\u00a0years of follow-up echocardiographic data without ERT, and (2) nine patients who had up to 12\u00a0years of follow-up data with ERT. The results showed that <jats:italic>z<\/jats:italic>-score changes of LVMI significantly improved in the patients who received ERT compared to those who did not receive ERT (0.05 versus 1.52, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). However, the severity score changes of MS, MR, AS, and AR all showed gradual progression in both groups (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>High prevalence rates of valvular heart disease and cardiac hypertrophy were observed in the MPS II patients in this study. The existence and severity of cardiac hypertrophy and valvular heart disease in these patients worsened with increasing age, reinforcing the concept of the progressive nature of this disease. ERT for MPS II appeared to be effective in stabilizing or reducing the progression of cardiac hypertrophy, but it only had a limited effect on valvulopathy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-021-01743-2","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T13:03:23Z","timestamp":1614085403000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Natural progression of cardiac features and long-term effects of enzyme replacement therapy in Taiwanese patients with mucopolysaccharidosis II"],"prefix":"10.1186","volume":"16","author":[{"given":"Hsiang-Yu","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Ren","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Lin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Miao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Lieh","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dau-Ming","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tung-Ming","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Kuang","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9619-0990","authenticated-orcid":false,"given":"Shuan-Pei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,23]]},"reference":[{"key":"1743_CR1","first-page":"3421","volume-title":"The metabolic and molecular bases of inherited disease","author":"EF Neufeld","year":"2001","unstructured":"Neufeld EF, Muenzer J. The mucoplysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B, editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill; 2001. p. 3421\u201352.","edition":"8"},{"key":"1743_CR2","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/mgg3.471","volume":"6","author":"HY Lin","year":"2018","unstructured":"Lin HY, Lee CL, Lo YT, Wang TJ, Huang SF, Chen TL, Wang YS, Niu DM, Chuang CK, Lin SP. The relationships between urinary glycosaminoglycan levels and phenotypes of mucopolysaccharidoses. Mol Genet Genomic Med. 2018;6:982\u201392.","journal-title":"Mol Genet Genomic Med"},{"key":"1743_CR3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1750-1172-6-72","volume":"6","author":"M Scarpa","year":"2011","unstructured":"Scarpa M, Alm\u00e1ssy Z, Beck M, Bodamer O, Bruce IA, De Meirleir L, et al. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis. 2011;6:72.","journal-title":"Orphanet J Rare Dis"},{"key":"1743_CR4","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ymgme.2017.05.016","volume":"121","author":"SA Khan","year":"2017","unstructured":"Khan SA, Peracha H, Ballhausen D, Wiesbauer A, Rohrbach M, Gautschi M, et al. Epidemiology of mucopolysaccharidoses. Mol Genet Metab. 2017;121:227\u201340.","journal-title":"Mol Genet Metab"},{"key":"1743_CR5","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/ajmg.a.32781","volume":"149A","author":"HY Lin","year":"2009","unstructured":"Lin HY, Lin SP, Chuang CK, Niu DM, Chen MR, Tsai FJ, et al. Incidence of the mucopolysaccharidoses in Taiwan, 1984\u20132004. Am J Med Genet A. 2009;149A:960\u20134.","journal-title":"Am J Med Genet A"},{"key":"1743_CR6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/BF01991908","volume":"154","author":"CF Wippermann","year":"1995","unstructured":"Wippermann CF, Beck M, Schranz D, Huth R, Michel-Behnke I, J\u00fcngst BK. Mitral and aortic regurgitation in 84 patients with mucopolysaccharidoses. Eur J Pediatr. 1995;154:98\u2013101.","journal-title":"Eur J Pediatr"},{"key":"1743_CR7","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s004310050872","volume":"157","author":"JH Dangel","year":"1998","unstructured":"Dangel JH. Cardiovascular changes in children with mucopolysaccharide storage diseases and related disorders\u2013clinical and echocardiographic findings in 64 patients. Eur J Pediatr. 1998;157:534\u20138.","journal-title":"Eur J Pediatr"},{"key":"1743_CR8","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/j.1651-2227.2002.tb03330.x","volume":"91","author":"UR Mohan","year":"2002","unstructured":"Mohan UR, Hay AA, Cleary MA, Wraith JE, Patel RG. Cardiovascular changes in children with mucopolysaccharide disorders. Acta Paediatr. 2002;91:799\u2013804.","journal-title":"Acta Paediatr"},{"key":"1743_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2143\/AC.60.1.2005049","volume":"60","author":"MR Chen","year":"2005","unstructured":"Chen MR, Lin SP, Hwang HK, Yu CH. Cardiovascular changes in mucopolysaccharidoses in Taiwan. Acta Cardiol. 2005;60:51\u20133.","journal-title":"Acta Cardiol"},{"key":"1743_CR10","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1017\/S1047951109003576","volume":"19","author":"V Fesslov\u00e1","year":"2009","unstructured":"Fesslov\u00e1 V, Corti P, Sersale G, Rovelli A, Russo P, Mannarino S, et al. The natural course and the impact of therapies of cardiac involvement in the mucopolysaccharidoses. Cardiol Young. 2009;19:170\u20138.","journal-title":"Cardiol Young"},{"key":"1743_CR11","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s10545-011-9359-8","volume":"34","author":"EA Braunlin","year":"2011","unstructured":"Braunlin EA, Harmatz PR, Scarpa M, Furlanetto B, Kampmann C, Loehr JP, et al. Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management. J Inherit Metab Dis. 2011;34:1183\u201397.","journal-title":"J Inherit Metab Dis"},{"key":"1743_CR12","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1017\/S104795110999062X","volume":"20","author":"GN Leal","year":"2010","unstructured":"Leal GN, de Paula AC, Leone C, Kim CA. Echocardiographic study of paediatric patients with mucopolysaccharidosis. Cardiol Young. 2010;20:254\u201361.","journal-title":"Cardiol Young"},{"key":"1743_CR13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10545-011-9444-z","volume":"36","author":"MM Brands","year":"2013","unstructured":"Brands MM, Frohn-Mulder IM, Hagemans ML, Hop WC, Oussoren E, Helbing WA, et al. Mucopolysaccharidosis: cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI. J Inherit Metab Dis. 2013;36:227\u201334.","journal-title":"J Inherit Metab Dis"},{"key":"1743_CR14","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.ymgme.2014.02.009","volume":"111","author":"SM Lin","year":"2014","unstructured":"Lin SM, Lin HY, Chuang CK, Lin SP, Chen MR. Cardiovascular abnormalities in Taiwanese patients with mucopolysaccharidosis. Mol Genet Metab. 2014;111:493\u20138.","journal-title":"Mol Genet Metab"},{"key":"1743_CR15","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ymgme.2016.02.003","volume":"117","author":"HY Lin","year":"2016","unstructured":"Lin HY, Chuang CK, Chen MR, Lin SM, Hung CL, Chang CY, et al. Cardiac structure and function and effects of enzyme replacement therapy in patients with mucopolysaccharidoses I, II, IVA and VI. Mol Genet Metab. 2016;117:431\u20137.","journal-title":"Mol Genet Metab"},{"key":"1743_CR16","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1136\/heartjnl-2015-309258","volume":"102","author":"E Braunlin","year":"2016","unstructured":"Braunlin E, Wang R. Cardiac issues in adults with the mucopolysaccharidoses: current knowledge and emerging needs. Heart. 2016;102:1257\u201362.","journal-title":"Heart"},{"issue":"2","key":"1743_CR17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3390\/diagnostics10020062","volume":"10","author":"HY Lin","year":"2020","unstructured":"Lin HY, Chuang CK, Lee CL, Chen MR, Sung KT, Lin SM, et al. Cardiac evaluation using two-dimensional speckle-tracking echocardiography and conventional echocardiography in Taiwanese patients with mucopolysaccharidoses. Diagnostics. 2020;10(2):62.","journal-title":"Diagnostics"},{"key":"1743_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/diagnostics11010016","volume":"11","author":"HY Lin","year":"2021","unstructured":"Lin HY, Chen MR, Lee CL, Lin SM, Hung CL, Niu DM, et al. Aortic root dilatation in Taiwanese patients with mucopolysaccharidoses and the long-term effects of enzyme replacement therapy. Diagnostics (Basel). 2021;11:16.","journal-title":"Diagnostics (Basel)"},{"key":"1743_CR19","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.amjcard.2006.02.047","volume":"98","author":"EA Braunlin","year":"2006","unstructured":"Braunlin EA, Berry JM, Whitley CB. Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I. Am J Cardiol. 2006;98:416\u20138.","journal-title":"Am J Cardiol"},{"key":"1743_CR20","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1007\/s10545-005-0211-x","volume":"28","author":"HY Lin","year":"2005","unstructured":"Lin HY, Lin SP, Chuang CK, Chen MR, Chen BF, Wraith JE. Mucopolysaccharidosis I under enzyme replacement therapy with laronidase\u2014a mortality case with autopsy report. J Inherit Metab Dis. 2005;28:1146\u20138.","journal-title":"J Inherit Metab Dis"},{"key":"1743_CR21","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s10545-009-1119-7","volume":"32","author":"SA Jones","year":"2009","unstructured":"Jones SA, Alm\u00e1ssy Z, Beck M, Burt K, Clarke JT, Giugliani R, et al. Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis. 2009;32:534\u201343.","journal-title":"J Inherit Metab Dis"},{"key":"1743_CR22","first-page":"59","volume":"15","author":"C Lavery","year":"2015","unstructured":"Lavery C, Hendriksz C. Mortality in patients with Morquio syndrome A. JIMD Rep. 2015;15:59\u201366.","journal-title":"JIMD Rep"},{"key":"1743_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13023-016-0471-6","volume":"11","author":"HY Lin","year":"2016","unstructured":"Lin HY, Chuang CK, Huang YH, Tu RY, Lin FJ, Lin SJ, et al. Causes of death and clinical characteristics of 34 patients with mucopolysaccharidosis II in Taiwan from 1995\u20132012. Orphanet J Rare Dis. 2016;11:85.","journal-title":"Orphanet J Rare Dis"},{"key":"1743_CR24","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","volume":"8","author":"J Muenzer","year":"2006","unstructured":"Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, et al. A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med. 2006;8:465\u201373.","journal-title":"Genet Med"},{"key":"1743_CR25","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","volume":"167","author":"JE Wraith","year":"2008","unstructured":"Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008;167:267\u201377.","journal-title":"Eur J Pediatr"},{"key":"1743_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ymgme.2009.08.006","volume":"99","author":"T Okuyama","year":"2010","unstructured":"Okuyama T, Tanaka A, Suzuki Y, Ida H, Tanaka T, Cox GF, et al. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II). Mol Genet Metab. 2010;99:18\u201325.","journal-title":"Mol Genet Metab"},{"key":"1743_CR27","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ymgme.2012.12.010","volume":"108","author":"G Tajima","year":"2013","unstructured":"Tajima G, Sakura N, Kosuga M, Okuyama T, Kobayashi M. Effects of idursulfase enzyme replacement therapy for mucopolysaccharidosis type II when started in early infancy: comparison in two siblings. Mol Genet Metab. 2013;108:172\u20137.","journal-title":"Mol Genet Metab"},{"key":"1743_CR28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ymgmr.2015.03.011","volume":"3","author":"R Parini","year":"2015","unstructured":"Parini R, Rigoldi M, Tedesco L, Boffi L, Brambilla A, Bertoletti S, et al. Enzymatic replacement therapy for Hunter disease: up to 9 years experience with 17 patients. Mol Genet Metab Rep. 2015;3:65\u201374.","journal-title":"Mol Genet Metab Rep"},{"key":"1743_CR29","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s10545-014-9686-7","volume":"37","author":"C Lampe","year":"2014","unstructured":"Lampe C, Bosserhoff AK, Burton BK, Giugliani R, de Souza CF, Bittar C, et al. Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series. J Inherit Metab Dis. 2014;37:823\u20139.","journal-title":"J Inherit Metab Dis"},{"key":"1743_CR30","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1515\/jpem-2019-0293","volume":"32","author":"B Bilginer Gurbuz","year":"2019","unstructured":"Bilginer Gurbuz B, Aypar E, Coskun T, Alehan D, Dursun A, Tokatli A, et al. The effectiveness of enzyme replacement therapy on cardiac findings in patients with mucopolysaccharidosis. J Pediatr Endocrinol Metab. 2019;32:1049\u201353.","journal-title":"J Pediatr Endocrinol Metab"},{"key":"1743_CR31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13023-014-0135-3","volume":"9","author":"CK Chuang","year":"2014","unstructured":"Chuang CK, Lin HY, Wang TJ, Tsai CC, Liu HL, Lin SP. A modified liquid chromatography\/tandem mass spectrometry method for predominant disaccharide units of urinary glycosaminoglycans in patients with mucopolysaccharidoses. Orphanet J Rare Dis. 2014;9:135.","journal-title":"Orphanet J Rare Dis"},{"key":"1743_CR32","doi-asserted-by":"publisher","first-page":"10755","DOI":"10.1038\/s41598-019-46829-x","volume":"9","author":"HY Lin","year":"2019","unstructured":"Lin HY, Lo YT, Wang TJ, Huang SF, Tu RY, Chen TL, et al. Normalization of glycosaminoglycan-derived disaccharides detected by tandem mass spectrometry assay for the diagnosis of mucopolysaccharidosis. Sci Rep. 2019;9:10755.","journal-title":"Sci Rep"},{"key":"1743_CR33","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/ijms21010114","volume":"21","author":"HY Lin","year":"2020","unstructured":"Lin HY, Tu RY, Chern SR, Lo YT, Fran S, Wei FJ, et al. Identification and functional characterization of IDS gene mutations underlying Taiwanese Hunter Syndrome (mucopolysaccharidosis type II). Int J Mol Sci. 2020;21:114.","journal-title":"Int J Mol Sci"},{"key":"1743_CR34","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ehjci\/jev014","volume":"16","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16:233\u201370.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"1743_CR35","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.amjcard.2016.11.064","volume":"119","author":"E Einarsen","year":"2017","unstructured":"Einarsen E, Cramariuc D, L\u00f8nnebakken MT, Boman K, Gohlke-B\u00e4rwolf C, Chambers JB, et al. Comparison of frequency of ischemic cardiovascular events in patients with aortic stenosis with versus without asymmetric septal hypertrophy (from the SEAS Trial). Am J Cardiol. 2017;119:1082\u20137.","journal-title":"Am J Cardiol"},{"key":"1743_CR36","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.echo.2003.12.005","volume":"17","author":"BW Eidem","year":"2004","unstructured":"Eidem BW, McMahon CJ, Cohen RR, Wu J, Finkelshteyn I, Kovalchin JP, et al. Impact of cardiac growth on Doppler tissue imaging velocities: a study in healthy children. J Am Soc Echocardiogr. 2004;17:212\u201321.","journal-title":"J Am Soc Echocardiogr"},{"key":"1743_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2008.11.029","volume":"22","author":"H Baumgartner","year":"2009","unstructured":"Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, et al. Echocardiographic assessment of valve stenosis: EAE\/ASE recommendations for clinical practice. J Am Soc Echocardiogr. 2009;22:1\u201323 (quiz 101\u2013102).","journal-title":"J Am Soc Echocardiogr"},{"key":"1743_CR38","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/ehjci\/jet105","volume":"14","author":"P Lancellotti","year":"2013","unstructured":"Lancellotti P, Tribouilloy C, Hagendorff A, Popescu BA, Edvardsen T, Pierard LA, et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2013;14:611\u201344.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"1743_CR39","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13023-018-0883-6","volume":"13","author":"HY Lin","year":"2018","unstructured":"Lin HY, Chen MR, Lin SM, Hung CL, Niu DM, Chuang CK, et al. Cardiac features and effects of enzyme replacement therapy in Taiwanese patients with mucopolysaccharidosis IVA. Orphanet J Rare Dis. 2018;13:148.","journal-title":"Orphanet J Rare Dis"},{"key":"1743_CR40","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13023-019-1112-7","volume":"14","author":"HY Lin","year":"2019","unstructured":"Lin HY, Chen MR, Lin SM, Hung CL, Niu DM, Chang TM, et al. Cardiac characteristics and natural progression in taiwanese patients with mucopolysaccharidosis III. Orphanet J Rare Dis. 2019;14:140.","journal-title":"Orphanet J Rare Dis"},{"key":"1743_CR41","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","volume":"18","author":"RM Lang","year":"2005","unstructured":"Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography\u2019s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440\u201363.","journal-title":"J Am Soc Echocardiogr"},{"key":"1743_CR42","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1161\/CIRCULATIONAHA.107.741157","volume":"117","author":"BJ Foster","year":"2008","unstructured":"Foster BJ, Mackie AS, Mitsnefes M, Ali H, Mamber S, Colan SD. A novel method of expressing left ventricular mass relative to body size in children. Circulation. 2008;117:2769\u201375.","journal-title":"Circulation"},{"key":"1743_CR43","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1136\/heart.83.6.667","volume":"83","author":"C Kampmann","year":"2000","unstructured":"Kampmann C, Wiethoff CM, Wenzel A, Stolz G, Betancor M, Wippermann CF, et al. Normal values of M mode echocardiographic measurements of more than 2000 healthy infants and children in central Europe. Heart. 2000;83:667\u201372.","journal-title":"Heart"},{"issue":"327\u2013331","key":"1743_CR44","first-page":"e2","volume":"159","author":"C Kampmann","year":"2011","unstructured":"Kampmann C, Beck M, Morin I, Loehr JP. Prevalence and characterization of cardiac involvement in Hunter syndrome. J Pediatr. 2011;159(327\u2013331):e2.","journal-title":"J Pediatr"},{"key":"1743_CR45","doi-asserted-by":"publisher","first-page":"E2004","DOI":"10.3390\/ijms17122004","volume":"17","author":"M Bolourchi","year":"2016","unstructured":"Bolourchi M, Renella P, Wang RY. Aortic root dilatation in mucopolysaccharidosis I\u2013VII. Int J Mol Sci. 2016;17:E2004.","journal-title":"Int J Mol Sci"},{"key":"1743_CR46","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1542\/peds.2006-2156","volume":"120","author":"JE Wraith","year":"2007","unstructured":"Wraith JE, Beck M, Lane R, van der Ploeg A, Shapiro E, Xue Y, et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics. 2007;120:e37-46.","journal-title":"Pediatrics"},{"key":"1743_CR47","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s10545-012-9481-2","volume":"36","author":"E Braunlin","year":"2013","unstructured":"Braunlin E, Rosenfeld H, Kampmann C, Johnson J, Beck M, Giugliani R, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme\u00ae) therapy. J Inherit Metab Dis. 2013;36:385\u201394.","journal-title":"J Inherit Metab Dis"},{"key":"1743_CR48","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10545-013-9649-4","volume":"37","author":"C Kampmann","year":"2014","unstructured":"Kampmann C, Lampe C, Whybra-Tr\u00fcmpler C, Wiethoff CM, Mengel E, Arash L, et al. Mucopolysaccharidosis VI: cardiac involvement and the impact of enzyme replacement therapy. J Inherit Metab Dis. 2014;37:269\u201376.","journal-title":"J Inherit Metab Dis"},{"key":"1743_CR49","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1542\/peds.2009-1728","volume":"125","author":"O Gabrielli","year":"2010","unstructured":"Gabrielli O, Clarke LA, Bruni S, Coppa GV. Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up. Pediatrics. 2010;125:e183-187.","journal-title":"Pediatrics"},{"key":"1743_CR50","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/j.1399-0004.2009.01324.x","volume":"77","author":"JJ McGill","year":"2010","unstructured":"McGill JJ, Inwood AC, Coman DJ, Lipke ML, de Lore D, Swiedler SJ, et al. Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age\u2014a sibling control study. Clin Genet. 2010;77:492\u20138.","journal-title":"Clin Genet"},{"key":"1743_CR51","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13023-015-0344-4","volume":"10","author":"NA Al-Sannaa","year":"2015","unstructured":"Al-Sannaa NA, Bay L, Barbouth DS, Benhayoun Y, Goizet C, Guelbert N, et al. Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: a retrospective case series analysis of nine sibships. Orphanet J Rare Dis. 2015;10:131.","journal-title":"Orphanet J Rare Dis"},{"key":"1743_CR52","doi-asserted-by":"crossref","unstructured":"Franco JF, Soares DC, Torres LC, Leal GN, Cunha MT, Honjo RS, et al: Short Communication Impact of early enzyme-replacement therapy for mucopolysaccharidosis VI: results of a long-term follow-up of Brazilian siblings. Genet Mol Res 2016, 15(1).","DOI":"10.4238\/gmr.15017850"},{"key":"1743_CR53","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ymgmr.2017.08.007","volume":"13","author":"M Furujo","year":"2017","unstructured":"Furujo M, Kosuga M, Okuyama T. Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI: 10-year follow up. Mol Genet Metab Rep. 2017;13:69\u201375.","journal-title":"Mol Genet Metab Rep"},{"key":"1743_CR54","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13023-018-0816-4","volume":"13","author":"CK Chuang","year":"2018","unstructured":"Chuang CK, Lin HY, Wang TJ, Huang YH, Chan MJ, Liao HC, et al. Status of newborn screening and follow up investigations for mucopolysaccharidoses I and II in Taiwan. Orphanet J Rare Dis. 2018;13:84.","journal-title":"Orphanet J Rare Dis"},{"key":"1743_CR55","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jpeds.2018.09.063","volume":"205","author":"MJ Chan","year":"2019","unstructured":"Chan MJ, Liao HC, Gelb MH, Chuang CK, Liu MY, Chen HJ, et al. Taiwan national newborn screening program by tandem mass spectrometry for mucopolysaccharidoses types I, II, and VI. J Pediatr. 2019;205:176\u201382.","journal-title":"J Pediatr"},{"key":"1743_CR56","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/1750-1172-8-147","volume":"8","author":"SP Lin","year":"2013","unstructured":"Lin SP, Lin HY, Wang TJ, Chang CY, Lin CH, Huang SF, et al. A pilot newborn screening program for mucopolysaccharidosis type I in Taiwan. Orphanet J Rare Dis. 2013;8:147.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"1743_CR57","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3390\/diagnostics9040140","volume":"9","author":"HY Lin","year":"2019","unstructured":"Lin HY, Lee CL, Lo YT, Tu RY, Chang YH, Chang CY, et al. An at-risk population screening program for mucopolysaccharidoses by measuring urinary glycosaminoglycans in Taiwan. Diagnostics (Basel). 2019;9(4):140.","journal-title":"Diagnostics (Basel)"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01743-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-021-01743-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01743-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T13:19:09Z","timestamp":1614086349000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01743-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,23]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1743"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01743-2","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,23]]},"assertion":[{"value":"2 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Declaration of Helsinki of 1975, as revised in 2000. The Institutional Review Board of MacKay Memorial Hospital approved this study, and written informed consent was obtained from all of the patients or their parents who were included in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication was obtained from all of the patients or their parents who were included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}